



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/725, 31/73	A1	(11) International Publication Number: WO 96/02259 (43) International Publication Date: 1 February 1996 (01.02.96)
<p>(21) International Application Number: PCT/SE95/00857</p> <p>(22) International Filing Date: 13 July 1995 (13.07.95)</p> <p>(30) Priority Data: 9402528-5 19 July 1994 (19.07.94) SE</p> <p>(71) Applicant (for all designated States except US): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): HANSSON, Hans- Arne [SE/SE]; Doteviksvägen 8, S-436 58 Hovås (SE). JOHANSSON-RUDÉN, Gunilla [SE/SE]; Bergstigen 20, S-436 42 Askim (SE). LARM, Olle [SE/SE]; Nyängsvägen 86, S-169 39 Bromma (SE).</p> <p>(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).</p>		<p>(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).</p> <p>Published With international search report.</p>
<p>(54) Title: HARD TISSUE STIMULATING AGENT</p> <p>(57) Abstract</p> <p>The use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate, chondroitinsulphates and dextran sulphate for the manufacture of an agent capable of providing stimulated regeneration of hard tissue; a process for stimulating regeneration of hard tissue in connection with so-called osseointegration; and implant intended for integration into hard tissue, particularly bone tissue.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HARD TISSUE STIMULATING AGENT

5 Technical area

The present invention relates to new techniques for stimulating or accelerating regeneration of hard tissue in connection with so called osseointegration, for example the effect sought in the implantation of foreign implants in hard tissue,
10 particularly bone tissue. The invention also relates to a process for carrying out such osseointegration while applying the new techniques according to the invention. Furthermore, the invention relates to the generation of new bone in relation to bone tissue defects or otherwise need of bone tissue.

15

Background of the invention

Implants intended for anchorage in hard tissue, particularly bone tissue, have enjoyed an ever increasing use in odontology, orthopedics, neurosurgery, hand
20 surgery and plastic and reconstructive surgery. Long term anchorage of implants in bone has been achieved with titanium, and it can be assumed that titanium-based materials also in the future will be used to a large extent as the material of choice for implants and prosthesis.

25 A clinical problem when dealing with so called osseointegration is the fact that the implant cannot be subjected to a load before sufficient bone anchorage has been achieved, which may require as much as 6 to 9 months. It is therefore clinically of utmost importance to accelerate the healing process by providing stimulated bone formation in association with the implants. There is also a need to regenerate bone
30 in order to bridge defects or sections where bone resorption has taken place in for

example toothless parts of jaws or where bone tissue has been lost due to e.g. trauma, tumor or surgery.

5 Summary of the invention

The main object of the present invention is to stimulate growth of cells in hard tissue, for example bone cells, so that the hard tissue volume will increase.

- 10 Another object of the invention is to provide means resulting in the formation of regenerated bone tissue of dominantly lamellar, compact type, whereas the extent of formation of scar tissue will be minimized.

- Yet an object of the invention is to provide a new agent capable of providing in
15 connection with implants in hard tissue stimulated regeneration of hard tissue, for example bone tissue.

- Another object of the invention is to provide a process for improved
osseointegration in connection with implantation of foreign implants in hard
20 tissue while stimulating regeneration of tissue.

Another object of the invention is to provide implants treated with an agent stimulating regeneration of hard tissue.

- 25 For these and other objects which will be clear from the following disclosure there is provided through the invention a new use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate, chondroitin-sulphates and dextran sulphate. This new use relates to the manufacture of an agent capable of providing stimulated regeneration of hard tissue. Such stimulated
30 regeneration may for example be provided in connection with implants in hard tissue, such as bone tissue.

The polysaccharide can be immobilized to the chitosan matrix in several ways, for example by ionic bonds, by covalent binding either multipoint or endpoint binding, or by mechanical fixation in the chitosan matrix in connection with
5 precipitation of the chitosan from solution. Ionic bonds and covalent bonds are preferred immobilization forms.

The hard tissue stimulating agent according to the invention may be present in different physical forms, for example as a membrane, a powder, a gel, beads or a
10 solution. In the case where an implant is intended, that part of the implant which is to be integrated in hard tissue can be dipped for application of the agent onto the implant. The agent can, of course, also be supplied to the hard tissue per se, for example in a cavity provided in bone tissue.

15 The material preferred for the implantation is titanium but other implant materials may as well be used.

Chitosan is a linear 1,4-bound polysaccharide built up from β -D-glucose amine units. The chitosan is manufactured by N-deacetylation of chitin, a polymer
20 forming the shell of *inter alia* insects and shellfish. Commercially, chitin is recovered from crab and shrimp shells which constitute waste products from the fishing industry. By controlling the alkali treatment of chitins, chitosans of varying degree of N-acetylation can be produced. When treating chitin with concentrated alkali, usually sodium hydroxide, N-deacetylation thus takes place, i.e. acetamido
25 groups are converted into amino groups to form chitosan.

The physical properties of chitosan affecting its usefulness depend on the degree of N-acetylation, the molecular weight and the homogeneity. Chitosan is biodegradable, both by chitinas in the digestive system and by lysozyme and other
30 enzymes in the body.

It is preferred in connection with the use of the present invention that the chitosan has a degree of N-acetylation of at most about 90% and preferably at most about 50%. It is particularly preferred that the degree of N-acetylation is less than about 25%.

The preferred polysaccharide for immobilization to the chitosan matrix is heparin or heparan sulphate. A special technique for covalent coupling of heparin to matrices containing amino groups is described in US patent No. 4,613,665.

10

The invention also provides for a process for stimulating and/or accelerating regeneration of hard tissue, for example in connection with so called osseointegration. This process is characterized in that before the implantation there is applied to the implant and/or the hard tissue a quantity suitable for stimulation of the defined agent prepared starting from chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate, chondroitin-sulphates and dextran sulphate. Osseointegration is the optimal form for long term anchorage of an implant of of non-autologous and various foreign materials into hard tissue, particularly bone tissue.

20

In connection with carrying out this process the agent may be applied in the form of a powder, a solution, a gel, beads, a film or a membrane. Alternatively, the agent may be applied by dipping that part of the implant intended to be integrated into hard tissue in a solution of the appropriate constituents chitosan and a polysaccharide immobilized thereto.

25

The invention also includes implants intended for integration in a hard tissue, particularly bone tissue. In such implants the part of the implant to be integrated is coated with an agent stimulating regeneration of hard tissue comprising chitosan and a polysaccharide immobilized to the chitosan and selected from heparin,

30

heparan sulphate, chondroitinsulphates and dextran sulphate. It is particularly preferred that the implant comprises titanium.

5 Examples of preferred embodiments

The present invention will in the following be illustrated by non-limiting examples. In these percentages and parts refer to weight if not otherwise stated.

10 EXAMPLE 1

Coating of a titanium screw with chitosan

Titanium screws are immersed into a 2% acetic acid solution of chitosan (1% w/v) and are allowed to remain in said solution for 15 min. The chitosan is Sea Cure 313, Pronova Biopolymer, 15% N-acetylation). The treated titanium screws are
15 then dried in a heat cabinet for 16 h at 70°C and then neutralized in 1 M NaOH and repeatedly rinsed with distilled water and again dried in a heat cabinet. The screws are packed in a package of the type "peel open" and sterilized with ethylene oxide.

20 EXAMPLE 2

Titanium screws with ionically bonded heparin

Screws coated with chitosan according to Example 1 are transferred into a solution consisting of 125 mg heparin (Pig Mucosa, Kabivitrum) in 500 mL of distilled water where they are allowed to remain for about 16 h, after which they are rinsed
25 in distilled water and dried at room temperature. The screws are packed in a package of the type "peel open" and sterilized with ethylene oxide. The amount of immobilized heparin is about $2 \mu\text{g}/\text{cm}^2$.

EXAMPLE 3

Titanium screws with covalently bonded heparin (End-point attachment)

Heparin is dissolved in water (300 mL). The solution is cooled to 0°C in ice water and maintained cold. First, there is added sodium nitrite (NaNO_2 , 10 mg) and then
5 acetic acid (2 mL) to the solution under stirring. The reaction mixture is maintained at 0°C for 2 h, dialyzed and freeze dried. The yield is 0.7 g.

Titanium screws coated with chitosan in accordance with Example 1 are transferred into a solution containing 125 mg of the above nitrite-degraded
10 heparin, 15 mg NaCNBH_3 , in 500 mL distilled water and pH is adjusted to 3.9 with 0.1 M HCl. The reaction mixture is maintained for about 16 h at room temperature. The screws are then rinsed in distilled water and dried at room temperature. The treated titanium screws are packed in a package of the type "peel open" and sterilized with ethylene oxide. The amount of immobilized heparin is about 1.5 μ
15 g/cm².

EXAMPLE 4

Titanium screws with covalently bonded heparin (multi-point attachment)

A solution of sodiumperiodate-oxidized sodiumheparin is prepared in the
20 following manner: One gram of sodiumperiodate NaIO_4 is dissolved in 200 mL of distilled water. Ten grams of sodiumheparin is added to the solution and the solution is stirred over night in the dark. The resulting solution, after adding 10 mL of glycerol and stirring for two hours, is dialyzed against water. The water is exchanged every other hour. This results in a solution containing periodate-
25 oxidized heparin in a concentration of about 19 mg/mL.

Titanium screws coated with chitosan in accordance with Example 1 are transferred to a solution containing 125 mg of the above periodate-oxidized

heparin, 15 mg NaCNBH_3 in 500 mL distilled water. The reaction is then performed exactly as described in Example 3.

EXAMPLE 5

5 Manufacture of chitosan film

5 g hydrochloride salt of chitosan (50% degree of acetylation, Pronova) are dissolved in distilled water (0.5 L, 1% v/w). 10 mL of the solution obtained are transferred to a Petri dish and a film of chitosan is formed by evaporation and drying in a heat cabinet at 70°C for 24 h. The film obtained is then neutralized by
10 the addition of a sodium phosphate buffer, 0.2 M, pH 9.0. The film is left in the Petri dish in this buffer at room temperature for 2-4 h, is then washed 3-4 times with water and allowed to dry.

EXAMPLE 6

15 Films with covalently bonded heparin (end-point attachment).

To a neutralized chitosan film prepared in accordance with Example 1 there are added 20 mL of a solution containing 125 mg nitrite degraded heparin, prepared as in Example 3, dissolved in 0.5 L water and containing 4.4 g NaCl. To the solution is added 15 mg sodium cyanoborohydride. The pH of the solution is
20 adjusted to 3.9 using 0.5 M hydrochloric acid or another acid. The solution containing the chitosan film is allowed to stand at room temperature for 14 h, and the treated film is then washed 3-4 times with water and is allowed to dry.

EXAMPLE 7

25 Films with ionically bonded heparin

To a neutralized chitosan film manufactured in accordance with Example 1 there is added 20 mL of a solution containing 125 mg heparin dissolved in 0.5 L water containing 4.4 g NaCl. The solution containing the chitosan film is allowed to stand at room temperature for 14 h, and the treated film is then washed 3-4 times

with water and allowed to dry. The produced film can be ground to a powder for use in osseointegration in accordance with the invention.

EXAMPLE 8

5 Biological test

As test animals there are used adult rabbits which are anaesthetized and prepared for the operation under sterile conditions, hair being removed in the knee region of the rabbit.

- 10 A distal skin section is made in the knee joint having a length of 35-40 mm against the tibia proximal part of the epiphys cartilage region. Periost is transected and under cooling by means of a continuously supplied sterile buffered saline solution there is drilled at a low rotation speed a hole through compact leg up to the marrow cavity using a 3.5 mm drill. Then there is proximally threaded an at 4 mm
- 15 long titanium screw having a hexagonal head and at 6 mm distally another titanium screw, both having a diameter of 3.5 mm. Facia and skin wound are sutured using single sutures. In the experiments there are used in addition to titanium screws treated according to the Examples 1-3 also untreated titanium screws.

20

- After 4 and 12 weeks, respectively, the rabbits are again anaesthetized. Hair is cut away in the knee region and skin incision is carried out distally of the knee joint towards tibia. The screws are dissected and identified, and the dethreading moment for the proximal screws is determined. The distal screws are prepared for
- 25 light microscopy with the implant remaining in the bone in situ.

EXAMPLE 9

Titanium powder with or without heparin coating

The coating of titanium powder with chitosan is performed essentially as described in Example 1 and the immobilisation is performed as described in
5 Example 3.

The fibula on either hind leg is exposed and its muscle tissue detached along an about 10 mm long distance on the mid shaft. A 6 mm long segment of the exposed fibula is removed, both the bone and its periosteum, and the defect between the
10 bone ends is filled with titanium powder. A membrane filter made of PTFE is wrapped around to bridge the defect and to prevent granulation tissue to invade the area. On one side titanium powder coated with heparin is positioned and on the other side non-coated titanium powder. The wounds are thereafter closed. The rats are allowed to move unrestricted during 3 weeks prior to a second
15 examination and sacrifice. Examination of the defects in the fibula on either side reveals that bone, cancellous and lamellar, is demonstrated to bridge both defects. However, the most extensive bone formation is formed at and along the heparinized titanium powder. Additionally, more lamellar i.e. well organized bone, is detected among the heparinized titanium powder.

20

Thus titanium powder coated with heparin as described above, stimulates new formation of bone even in the absence of periosteum.

EXAMPLE 10

Osteogenic activity of ionically heparinized chitosan membrane as assessed by the fibula gap bridging technique

The fibula on either hind leg is exposed on anaesthetized rats and its muscle tissue detached along an about 10 mm long distance on the mid shaft. A 6 mm long segment of the exposed fibula is removed, both the bone and its periosteum, and
30 the defect between the bone ends is wrapped with a chitosan film.

On the left side a chitosan membrane prepared as in Example 5, is positioned (chitosan with 15% acetylation) and on the right fibula defect a heparinized chitosan membrane prepared as in Example 7 (chitosan with 15% acetylation) is positioned.

5

To avoid that the tube, created by the membranes and bridging the 6 mm gap between the bone ends, collapses, small bone fragments are positioned along the gap.

- 10 At examination after three weeks a more prominent formation of bone matrix and of bone could be demonstrated in both animals on the right side, i.e. the one with the heparinized chitosan film.

EXAMPLE 11

- 15 Osteogenic activity of heparinized chitosan membrane as assessed by bone formation in a hole in the calvarium

It is well established that if defects exceeding certain dimensions are created in bone, such defects are healed by the formation of a fibrous scar tissue membrane bridging the defect in the bone. The critical size for holes in the calvarium in adult
20 rats is 8 mm, i.e. holes 8 mm or of large diameter will not be closed by bone tissue.

In rats a paramedial skin incision is made from the nasofrontal area to the external occipital protuberance. The skin and the underlying tissues, including most of the temporal muscle on either side, are detached. A specially manufactured trephine is
25 used to create a 8 mm hole in the skull bilaterally. Extreme care is taken to avoid damage to the meninges and the brain.

On the right side a chitosan membrane with ionically bonded heparin prepared as in Example 9 s placed on the dura, multiple bone fragments positioned on the
30 membrane and an additional identical membrane positioned on the skull.

Thereafter, on the left side a non-heparinized chitosan membrane prepared as in

Example 5 is positioned in the same way with spacing bone fragments. Thereafter, the galea and the skin are closed.

After 3 weeks the rats are anaesthetized and the skull examined. More osteoid and
5 new bone tissue could be demonstrated to cover the defect on the right side as compared to the left side. There is in addition less prominent inflammatory reaction at the heparinized chitosan membranes.

EXAMPLE 12

10 Preparation of chitosan beads covered with dextran sulphate or heparin or chondroitin-4-sulphate.

Aqueous solutions of chitosan (2% w/v, 18% acetylated) is added drop by drop with a syringe to a solution of dextran sulphate or heparin or chondroitin-4-sulphate (0.1% w/v) in tripolyphosphate buffer. The resulting beads are recovered
15 on a glass filter and rinsed with water (1L) and dried at 30 °C over night.

EXAMPLE 13

Osteogenic activity of chitosan beads as assessed by bone formation after subperiosteal deposition on the skull

20 Positioning of a compound to be tested for osteogenic activity under the periosteum of the skull is a well established method.

Beads made of chitosan and heparin, chitosan coated with dextran sulphate and chitosan coated with chondroitin-4-sulphate, pared as described in Example 12,
25 are positioned subperiosteally on the frontal bone of adult rats. One such bead is positioned on either side. Bone formation is assessed after 3 weeks.

Chitosan-heparin beads are osteogenic as revealed by the formation of osteoid and bone tissue on the frontal bone. The chondroitinsulphate coated chitosan beads
30 and the dextran sulphate coated ones do also show osteogenic activity. Inflammatory cells could be recognized to variable, usually low, extent as well.

These experiments demonstrate that chitosan combined with certain polysaccharides exert osteogenic activity.

- 5 Even better stimulation of healing quality can probably be achieved by a combination of this invention with growth factors.

Experiments in vitro with aFGF labelled with iodine 125 (acidic Fibroblast Growth Factor, Bachem California) show a significantly higher specific binding of growth factor to a heparinized screw as compared to a non-heparinized screw. Even if the
10 invention is not restricted to any particular theory it seems likely that endogeneous growth factors are enriched at the interface between implant and surrounding bone when the screw is provided with a coating of chitosan-heparin, thus resulting in stimulated bone regeneration.

- 15 The invention is not limited to the embodiments described but is applicable to all forms of implant intended for integration into hard tissue, particularly bone tissue. Thus, the invention is applicable within all areas, for example odontology, orthopedics, neurosurgery, hand surgery and plastic and reconstructive surgery. Also with regard to dental applications the invention is quite useful.

CLAIMS

1. The use of chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate, chondroitinsulphates and dextran sulphate for the
5 manufacture of an agent capable of providing stimulated regeneration of hard tissue.

2. The use according to claim 1, characterized in that stimulated regeneration of hard tissue is provided in connection with implants in hard tissue, such as bone
10 tissue.

3. The use according to claim 1 or 2, characterized in that the polysaccharide is immobilized to the chitosan by ionic bonds.

15 4. The use according to claim 1 or 2, characterized in that the polysaccharide is immobilized to the chitosan by means of covalent bonds.

5. The use according to any one of the preceding claims, characterized in that the polysaccharide is heparin or heparan sulphate.
20

6. The use according to any one of the preceding claims, characterized in that the agent is in the form of a powder or a solution.

7. The use according to any one of claims 1 to 5, characterized in that the agent
25 is in the form of a gel.

8. The use according to any one of claims 1 to 5, characterized in that the agent is in the form of beads.

9. The use according to any one of the preceding claims, characterized in that the chitosan has a degree of N-acetylation of at most about 90% and preferably at most about 50%.
- 5 10. The use according to claim 9, characterized in that the chitosan has a degree of N-acetylation of less than about 25%.
11. The use according to any one of claims 2 to 10, characterized in that the implant comprises titanium.
- 10 12. A process to stimulate and/or accelerate regeneration of hard tissue, characterized by applying onto the appropriate site an amount active for stimulation of an agent comprising chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate, chondroitinsulphates and
- 15 dextran sulphate.
13. A process according to claim 12, wherein the regeneration is in connection with osseointegration.
- 20 14. A process according to claim 13, characterized in that the osseointegration is carried out in connection with implants in hard tissue, such as bone tissue.
15. A process according to claims 12 to 14, characterized in that said agent is applied in the form of a powder.
- 25 16. A process according to claims 12 to 14, characterized in that said agent is applied in the form of a gel.
17. A process according to any one of claims 12 to 16, characterized in that the
- 30 polysaccharide is constituted by heparin or heparan sulphate.

18. A process according to claims 13, 14 or 17, characterized in that the agent is applied by dipping of that part of the implant which is to be integrated into hard tissue in a solution of chitosan and polysaccharide.

- 5 19. Implant intended for integration in hard tissue, characterized in that at least that part of the implant which is to be integrated is coated with an agent stimulating regeneration of hard tissue comprising chitosan and a polysaccharide immobilized thereto selected from heparin, heparan sulphate, chondroitinsulphates and dextran sulphate.

10

20. Implant according to claim 19, characterized in that it comprises titanium.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00857

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 31/725, A61K 31/73

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CA, WPI, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Biomaterials, Volume 14, No 12, 1993, R.A.A. Muzzarelli et al, "Osteoconductive properties of methylpyrrolidinone chitosan in an animal model", see page 928 --	1-11,19-20
A	Swedish dental journal/Supplement, Volume 64, 1989, L. Peter Nilsson, "Effects of Hyperbaric Oxygen Treatment of Bone Healing" page 19 - page 25 -- -----	1-11,19-20

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

& document member of the same patent family

Date of the actual completion of the international search

19 October 1995

Date of mailing of the international search report

10-11-1995

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Anna Sjölund
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/00857

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 12-18
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.